mitefnyc-outsmartingcancer.splashthat.comOutsmarting Cancer: How New Technologies Are Tackling A Cure

It looks like you’re using an outdated browser. For an optimized experience,to one of our recommended options. Learn More Outsmarting Cancer: How New Technologies are Tackling a Cure 05 . 22 . 2017 Register Text goes here X 1. What are the best ways to engage and encourage new investors? Dustin Lucien Chief Operating Officer Betterment Dustin Lucien is the Chief Operating Officer of Betterment and has been with the company since 2013. Prior to becoming COO, Dustin served as Betterment’s Chief Technology Officer, as well as the VP of Engineering. Dustin received his Bachelor’s degree in Biomedical Engineering at Case Western Reserve University, as well as his Master’s degree in Biomedical Imaging & Computing. Mrs Robinson Wishes you a wonderful day Dustin Lucien Chief Operating Officer Betterment Dustin Lucien is the Chief Operating Officer of Betterment and has been with the company since 2013. Prior to becoming COO, Dustin served as Betterment’s Chief Technology Officer, as well as the VP of Engineering. Dustin received his Bachelor’s degree in Biomedical Engineering at Case Western Reserve University, as well as his Master’s degree in Biomedical Imaging & Computing. Events MembershipBlog Sponsors Contact Us MITEF NYC Expert Panel Outsmarting Cancer: How New Technologies are Tackling a Cure May 22 , 2017 | 5:30pm – 8:30pm Register Now Text goes here X 5:30 PM - 6:15 PM Reception 6:15 PM - 7:45 PM Panel Discussion 7:45 PM - 8:30 PM Q&A and Networking Hughes Hubbard & Reed LLP New York, NY 10004 Truly the emperor of maladies, cancer remains a formidable opponent, poised to overtake cardiovascular disease as the leading cause of death in the US. It is estimated that 1 in 2 will get cancer in their lifetimes and 1 in 4 will die of the disease. New developments, however, offer hope that we can halt or reverse these trends. Our esteemed panel will discuss recent advances in genomics, big data, and machine learning that promise to deliver dramatic improvements in survival through earlier and more accurate diagnoses and better treatment choices. Come learn about: - How new diagnostics, including gene sequencing, are uncovering the molecular signature of tumors, helping direct treatment: - How collecting and sharing real world data can similarly help reveal patterns, leading to better outcomes - How new therapies, including cell therapy and immunotherapy, are improving cure rates across a number of tumor types Join a lively conversation on the latest developments in cancer and how Fortune 500 companies, startups, nonprofits and cancer centers are all investing in the next breakthrough. Refreshments courtesy of White and Williams LLP Hosted by Hughes Hubbard Reed LLP KEY QUESTIONS 1. What are the best ways to engage and encourage new investors? 2. How is finance leveraging today’s mobile, web and cloud technologies? 3. How can this reduce costs for investors, banks and financial institutions? Keynote Come listen to five startups in the early stages of building their businesses present their plans. Join our esteemed panel of industry experts to gain insight into where the best opportunities are to invest in FinTech today. As in the past, this event is interactive – both the panel of experts and the audience will weigh in on and ask pivotal questions to the presenting startups. Julia A. Elvin, MD PhD VP & Senior Associate Medical Director Foundation Medicine, Inc Dr. Elvin joined Foundation Medicine in January 2014 as Associate Medical Director and Senior Pathologist with 8 years of experience in diagnostic pathology, cytology and laboratory medicine as Associate Medical Director and Director of Women’s Health Pathology in a regional reference pathology laboratory (Converge Diagnostic Services). Dr. Elvin has a particular interest in both the molecular drivers of cancer and gynecologic pathology. She was a trainee in the MSTP program at Baylor College of Medicine in Houston, TX where she obtained her MD and PhD in Human and Molecular Genetics studying female reproductive system effects of TGF-beta family members using knockout mouse models. Her anatomic pathology training included an internship at the Baylor Affiliated Hospitals Pathology program, Anatomic Pathology residency and Women’s and Perinatal Pathology fellowship at Brigham and Women’s Hospital in Boston, MA where she also served as Chief Resident. At Foundation Medicine, Dr. Elvin explores the genomic underpinnings of a diverse array of tumor types, presenting results at national and international pathology and oncology meetings, including USCAP, SGO, ASCO, and ESMO. Dr. Elvin has authored and co-authored numerous abstracts, reviews, book chapters and peer-reviewed articles, which have appeared in such journals as Proceedings of the National Academy of Science USA, Nature, JAMA Oncology, Gynecologic Oncology, The Oncologist, Clinical Cancer Research, and American Journal of Surgical Pathology. Panelists Come listen to five startups in the early stages of building their businesses present their plans. Join our esteemed panel of industry experts to gain insight into where the best opportunities are to invest in FinTech today. As in the past, this event is interactive – both the panel of experts and the audience will weigh in on and ask pivotal questions to the presenting startups. Andrew L. Pecora, MD, FACP CPE Chief Innovations Officer President , Physician Services Division Chief Innovations Officer , Hackensack Meridian Health Founder and First President , Regional Cancer Care Associates Dr. Andrew Louis Pecora is President of the Physicians Services Division and Chief Innovations Officer, Hackensack Meridian Health. He is the founder and served as President of Regional Cancer Care Associates. He is a Professor Medicine at UMDNJ- New Jersey Medical School and Professor of Oncology and Medicine at Georgetown University. Dr. Pecora has received the American Cancer Society Physicians in the Forefront Award (1997) and the Susan G. Komen Breast Cancer Foundation Award as a Hero in the fight against breast cancer (1998). He received the EBMT-ESMO Award at the International Conference on High dose chemotherapy in Breast and Ovarian Cancer in 2000. Dr. Pecora has been honored by the March of Dimes (2007), inducted into the Nutley Hall of Fame (2005) and given the distinguished citizen award by the Hackensack chamber of commerce for his contributions to research and patient care (2001). Dr Pecora received the Uber Elite Award in 2016. Dr. Pecora is also an entrepreneur having co-founded and served as Chairman and Chief Executive Officer of Progenitor Cell Therapy, L.L.C.; a company focused on facilitating the transfer of laboratory breakthrough to clinical application and practice in cell therapies. He also co-founded and served as Chairman of Amorcyte, Inc. a biotechnology company developing cell therapies for cardiovascular disease and founded COTA a healthcare software analytic company focused on enabling value based care delivery and serves as its Executive Chairman. He served on the board of Cancer Genetics and was chairman of the board of Tetralogics, Inc., a company developing small molecules to treat cancer. Andrew Norden, MD, MPH, MBA Chief Operating Officer Deputy Chief Health Officer , IBM Watson Health Assistant Professor of Neurology , Harvard Medical School Attending Neuro Oncologist , Dana Farber Cancer Institute Dr. Norden serves as Deputy Chief Health Officer with a leadership role in oncology and genomics. He is an oncologist and physician executive who joined Watson Health in 2016 after serving as Associate Chief Medical Officer at Dana-Farber Cancer Institute. At Dana-Farber, Andrew led the Dana-Farber community network for more than 5 years. He was responsible for physician mentorship and supervision, quality improvement, patient safety, program development, clinical trials, implementation of a medical oncology clinical pathways program,...